Company Overview
LifeMD, Inc. operates as a direct-to-patient telehealth company that engages in providing patients with access to virtual medical care and pharmacy services within the United States. The company functions specifically within the Healthcare sector and the Health Information Services industry, indicating its focus on digital health solutions rather than traditional brick-and-mortar medical facilities. LifeMD, Inc. employs 347 individuals and holds a Price to Book ratio of 47.00, though the market cap is listed as N/A in available data. The absence of a reported market cap figure combined with a Price to Book ratio of 47.00 suggests significant market volatility or specific structural characteristics that prevent standard capitalization metrics from reflecting the company's typical valuation scale. The reported annual revenue of $194.06M provides a tangible measure of operational scale, while the employee count of 347 indicates a lean operational structure relative to the revenue generated. This revenue figure, when contrasted with the lack of a standard market cap, highlights a potential disconnect between current trading prices and underlying asset value, which is a critical consideration for analysts evaluating the firm's position in the health information services landscape.
Financial Health
The company reports a trailing twelve-month revenue of $194.06M, while simultaneously reporting a net income of $-14,604,168 and an EBITDA of $-6,710,168. The substantial gap between the positive revenue of $194.06M and the negative net income reveals a cost structure where operating expenses and other deductions significantly outweigh the revenue generated, resulting in a net loss. Free cash flow stands at $-10,155,929, which indicates that the company is currently burning cash and lacks the financial flexibility to fund operations or growth without external capital infusion. The gross margin is reported at 85.7%, suggesting high efficiency in the direct cost of goods sold relative to revenue, yet this is offset by an operating margin of -2.3% and a profit margin of 7.4%. The disparity between the gross margin of 85.7% and the negative operating margin of -2.3% indicates that while the core service delivery is profitable on a gross basis, overhead costs and administrative expenses are consuming those margins to the point of overall operational loss. Total cash on hand is $36.79M, which exceeds the total debt of $6.32M, but the debt-to-equity ratio of 27.31 suggests a highly leveraged position relative to equity, though the absolute debt level is low compared to cash reserves. The current ratio of 1.25 indicates that the company possesses sufficient current assets to cover its short-term liabilities, providing a baseline level of liquidity despite the cash burn. Return on Equity is -131.2% and Return on Assets is -6.5%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate profit, as negative returns indicate that operations are not covering the cost of capital employed.
Valuation Assessment
The trailing P/E and forward P/E are both listed as N/A, which implies that standard earnings-based valuation models cannot be applied due to the company's lack of positive earnings, making any comparison of earnings trajectories impossible using these specific metrics. The price-to-book ratio is 47.00, a figure that indicates the market is pricing the company at a massive premium over its book value, suggesting that investors are valuing intangible assets or future growth potential far beyond the tangible assets recorded on the balance sheet. The price-to-sales ratio is N/A and the EV/EBITDA is -162.11, suggesting that alternative valuation metrics are also skewed by negative earnings and the absence of a standard market cap, which complicates direct comparisons with profitable peers. The 52-week high is $26.99 and the 52-week low is $18.50, but the current trading price cannot be mathematically located relative to this range as a specific share price is not provided in the facts, only the high and low bounds. The beta value is 2.01, which means the stock price exhibits more than double the volatility of the broader market, indicating that price movements will likely be amplified during periods of market stress or rally. The EV/EBITDA of -162.11 further underscores the difficulty in applying traditional multiple-based valuation methods given the negative EBITDA, reinforcing the N/A status of other key multiples like P/E and P/S.
Growth & Income
Revenue growth year-over-year is -27.1%, while earnings growth is N/A, indicating that the company is experiencing a contraction in revenue and lacks a positive earnings growth trajectory to analyze. Since earnings are negative, they cannot grow faster than revenue in the traditional sense, and the decline in revenue of -27.1% suggests a challenging market environment or loss of market share within the telehealth sector. The dividend yield is 9.5%, but the payout ratio is N/A, which creates a sustainability concern because a high yield derived from negative net income of $-14,604,168 is not supported by actual distributable earnings. Given the negative net income and the N/A payout ratio, the company is effectively unable to pay dividends from earnings, meaning the reported yield likely reflects a share price depression rather than actual income distribution from profits. The overall growth and income profile is characterized by significant revenue contraction, negative earnings, and a dividend yield that is mathematically unsustainable given the financial losses reported for the trailing twelve months.